Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Systemic VEGF Effects of Anti-VEGF Agents in AMD
NCT02296567Phase 3Unknown
- Sponsor
- East Florida Eye Institute
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab, bevacizumab, aflibercept in age-related macular degeneration (AMD), sponsored by East Florida Eye Institute. Status: unknown.
02
Drugs
ranibizumabbevacizumabaflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02296567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296567.